ATM and neoplasm: These results argue that transformed human and murine pancreatic cells respond differently to the dosage of ATM, although it is also possible that in our KCATMΔ+ tumor cells additional mutations or oncogenic events bypassed the need to inactivate the wildtype Atm allele.